IGC Pharma/$IGC
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About IGC Pharma
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
- Ticker
- $IGC
- Sector
- Health
- Primary listing
- AMEX
- Employees
- 70
- Headquarters
- Potomac, United States
- Website
- igcpharma.com
IGC Pharma Metrics
BasicAdvanced
$21M
-
-$0.08
0.55
-
Price and volume
Market cap
$21M
Beta
0.55
52-week high
$0.39
52-week low
$0.08
Average daily volume
557K
Financial strength
Current ratio
1.324
Quick ratio
0.787
Long term debt to equity
0.017
Total debt to equity
0.018
Profitability
EBITDA (TTM)
-7.524
Gross margin (TTM)
46.20%
Net profit margin (TTM)
-582.82%
Operating margin (TTM)
-731.92%
Revenue per employee (TTM)
$20,000
Management effectiveness
Return on assets (TTM)
-50.31%
Return on equity (TTM)
-83.34%
Valuation
Price to revenue (TTM)
14.871
Price to book
2.26
Price to tangible book (TTM)
5.69
Price to free cash flow (TTM)
-2.626
Free cash flow yield (TTM)
-38.07%
Free cash flow per share (TTM)
-0.076
Growth
Revenue change (TTM)
-6.51%
Earnings per share change (TTM)
-57.08%
3-year revenue growth (CAGR)
17.72%
10-year revenue growth (CAGR)
-18.65%
3-year earnings per share growth (CAGR)
-34.20%
10-year earnings per share growth (CAGR)
-9.84%
IGC Pharma Financial Performance
Revenues and expenses
IGC Pharma Earnings Performance
Company profitability
Upcoming events
No upcoming events
IGC Pharma News
AllArticlesVideos
IGC Pharma Unveils PRISM AI Platform to Move Alzheimer's Risk Prediction to Brain-Health Action and Commercial Deployment
Accesswire1 month ago
IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026
Accesswire1 month ago
IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure
Accesswire3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.